Article
Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Jun 2022
Rudra Sharmistha, Shaul Eliana, Conrad Maire, Patel Trusha, Moore Astrela, Dawany Noor, Canavan Megan C, Sullivan Kathleen E, Behrens Edward, Kelsen Judith R
Abstract excerpt
Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD1; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.